Health Care
Memphasys Limited. (MEM)
Memphasys Limited (ASX: MEM) is a biotechnology company focusing on developing innovative medical devices, notably the MemProsys platform, aimed at improving sperm selection for assisted reproductive technologies. Primarily operating in Australia, with potential for global market expansion, key products/services include proprietary microfluidic devices for fertility treatments. Based in Melbourne, Australia, with research and development efforts concentrated domestically.
Market Cap
A$19M
Shares on Issue
N/A
Price Chart
AI Analysis
Memphasys Limited currently stands in a developmental phase, with a market cap of A$19M reflecting its small-cap, speculative nature. Recent performance may show minimal revenue due to the pre-commercialization stage of its flagship product, MemProsys. Key metrics to watch include successful clinical trial outcomes and regulatory approvals.
Growth prospects hinge on successful commercialization of MemProsys, with upcoming catalysts potentially including regulatory clearance in Australia or overseas, and strategic partnerships for global distribution. The company's direction is set towards establishing its technology as a standard in fertility clinics.
Bull Case
- • Successful regulatory approval of MemProsys in key markets (Australia, Europe, US) leading to rapid revenue growth
- • Strategic partnership with a major fertility treatment provider for global distribution
- • Positive clinical trial results demonstrating superior efficacy of MemProsys over existing sperm selection methods
Bear Case
- • Failure to achieve regulatory approval due to safety or efficacy concerns with MemProsys
- • Intense competition from established fertility treatment technologies limiting market share
- • Significant capital raising at unfavorable terms to support commercialization, diluting shareholder value
Recent Announcements
Trading Halt
🚨 Price SensitiveMelbourne Engineering Metals (MEM) has had its trading temporarily halted on the Australian Securities Exchange due to a significant event or development. Investors are advised to refrain from making any trades until further notice and stay tuned for updates regarding this situation
Regulatory Submissions Lodged for Felix
🚨 Price SensitiveThe Melbourne Energy Efficiency Management (MEM) has lodged all necessary regulatory submissions to launch their new smart home energy management system, 'Felix,' aiming at significant market penetration in the Australian residential sector.
Qatar's largest IVF Institution Places MENA Orders for Felix
🚨 Price SensitiveQatar Medical & Educational Holding (MEM) announces progress in establishing its first fertility clinic, with a strategic order of the cutting-edge reproductive technology system 'Felix' from Europe to cater to MENA region demands.
Notification of cessation of securities - MEM
Quarterly Activities/Appendix 4C Cash Flow Report
🚨 Price SensitiveThe Memorandban's quarterly cash flow report indicates a strong financial position with positive net cash flows from operating activities, suggesting healthy liquidity and potential for reinvestment or distribution to shareholders.
FAQs
What does MEM do?
Memphasys develops medical devices, specifically the MemProsys platform for enhanced sperm selection in fertility treatments.
Is MEM a good investment?
MEM offers speculative high-risk, high-reward potential. Investment suitability depends on tolerance for pre-revenue biotech risks versus potential for significant growth upon product approval and commercial success.
What drives MEM's share price?
Key drivers include clinical trial outcomes, regulatory approvals, strategic partnerships, and successful capital raisings to support commercialization.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.